23 results
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
liability and the further development of obicetrapib could be delayed. Similarly, if an actual or attempted security incident were to occur we may … . Furthermore, if we are required to disclose the occurrence of a cybersecurity incident, the price of our Ordinary Shares may be negatively impacted
10-K
2023 FY
NAMS
NewAmsterdam Pharma Company NV
28 Feb 24
Annual report
8:00am
those incident to our formation and certain matters related to the Business Combination, such as the making of certain required securities law filings … could incur liability and the further development of obicetrapib could be delayed. Similarly, if an actual or attempted security incident were
8-K
EX-1.1
NAMS
NewAmsterdam Pharma Company NV
15 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
4:18pm
contemplated hereby, including without limitation (i) all expenses incident to sale and delivery of the Offered Securities (including all printing
F-3
EX-1.2
NAMS
NewAmsterdam Pharma Company NV
7 Dec 23
Shelf registration (foreign)
4:16pm
the following expenses all incident to the performance of its obligations hereunder, including, but not limited to, expenses relating to (i) the preparation
424B3
NAMS
NewAmsterdam Pharma Company NV
15 Aug 23
Prospectus supplement
4:52pm
of the Business Combination, we had not conducted any material activities other than those incident to our formation and the matters contemplated by the Business … or security incident were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary
POS AM
suoic8n90n g3h
7 Aug 23
Prospectus update (post-effective amendment)
7:56am
6-K
EX-99.2
bc7rr
7 Aug 23
Research and development expenses
7:24am
424B3
bto51bnco8 vxrw
9 Jun 23
Prospectus supplement
9:43pm
6-K
EX-1.1
965pqyqb387q0vrbc9
9 Jun 23
Current report (foreign)
9:39pm
424B3
wfd5hsq66ilf
8 Jun 23
Prospectus supplement
5:01pm
424B3
09fj cg498s8j7w
6 Jun 23
Prospectus supplement
4:20pm
424B3
onb8wppi290j 08d
25 Apr 23
Prospectus supplement
8:14am
POS AM
whoia 0xcjsvb
17 Apr 23
Prospectus update (post-effective amendment)
9:09am
F-1
ag3iwji1k44s2
19 Dec 22
Registration statement (foreign)
6:22pm
20-F
wkfseik5
28 Nov 22
Annual report (foreign)
4:41pm
6-K
EX-2.1
x9enh27i22 zrq
23 Nov 22
Current report (foreign)
4:36pm
424B3
mq8z57n9
18 Oct 22
Prospectus supplement
4:41pm
F-4/A
mtr9u2dwq66eenqbfy9
13 Oct 22
Registration of securities (foreign) (amended)
5:18pm
F-4/A
0wi53 59a4azpjz3781b
3 Oct 22
Registration of securities (foreign) (amended)
5:12pm